Finally, studies performed in mice bearing prostate cancers or melanomas, have shown that low doses of NGR-TNF can enhance the infiltration of effector T cells in tumors, as well as the therapeutic effects of immune checkpoint blockers combined with adoptive cell therapy [43]. This evidence concerns the gene RTN4R and prostate carcinoma.